Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 2/20 | 0.49 |
| ▸ | MPL | P40238 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30201480 | 1.00 | MAPT (0.63) | MAPTKMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL2220908 | 0.90 | ALDH1A1 (0.57) | MAPTKMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL14651018 | 0.88 | SMN1; SMN2 (0.58) | MAPTKMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL29643236 | 0.88 | MAPT (0.70) | MAPTKMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL1586929 | 0.88 | MAPT (0.70) | MAPTKMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL30571064 | 0.86 | MAPT (0.62) | MAPTKMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL10738593 | 0.86 | MAPT (0.68) | MAPTKMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL4283723 | 0.84 | MAPT (0.66) | MAPTKMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL2485234 | 0.82 | MAPT (0.61) | MAPTKMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL6688391 | 0.81 | MAPT (0.60) | MAPTKMT2AKDM4ESMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004063156-A1 | NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS | BIOVITRUM AB (SE) | 2004-07-29 | — | — | WO | claimed |
| EP-4376818-B1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2025-06-18 | — | — | EP | disclosed |
| US-12209084-B2 | Serotonin 5-HT2B inhibitory compounds | ZOETIS SERVICES LLC (US) | 2025-01-28 | — | — | US | disclosed |
| EP-4376818-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | Zoetis Services LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-117729914-A | Serotonin 5-HT2B inhibiting compounds | 硕腾服务有限责任公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20230071039-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC | 2023-03-09 | — | — | US | disclosed |
| WO-2023009330-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | ZOETIS SERVICES LLC (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20170158636-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-08 | — | — | US | disclosed |
| US-20170158636-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-08 | — | — | US | disclosed |
| US-20170158636-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-08 | — | — | US | disclosed |
| WO-2016008010-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016008010-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
| US-8076348-B2 | Acylguanidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| EP-1923387-B1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-2119704-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-1923387-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2004063156-A1 | NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS | BIOVITRUM AB (SE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230071039-A1 | SEROTONIN 5-HT2B INHIBITORY COMPOUNDS | HTR2B, HTR1B, HTR1A | MAPT 4351/4885KMT2A 3310/4885KDM4E 2243/4885 |
| US-20170158636-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | MAPT 2160/4885KMT2A 2749/4885KDM4E 2581/4885 |
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | HTR5A, GRM5, HTR1E | MAPT 348/4885KMT2A 1785/4885KDM4E 731/4885 |
| US-12209084-B2 | Serotonin 5-HT2B inhibitory compounds | HTR2B, HTR1B, HTR1A | MAPT 4351/4885KMT2A 3310/4885KDM4E 2243/4885 |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | HTR2B, HTR7, HTR3B | MAPT 4231/4885KMT2A 2115/4885KDM4E 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.